摘要
目的观察2型糖尿病(T2DM)患者围手术期甘精胰岛素治疗的临床疗效及安全性。方法将60例拟行手术治疗的T2DM患者分为甘精胰岛素治疗组(Gla组,30例)及分次皮下注射胰岛素组(MDI组,30例),控制围手术期血糖。根据血糖监测结果调整药物剂量,比较2组患者降糖疗效及安全性。结果两组均可有效降低血糖(P<0.01),降糖效果无明显差异(P>0.05)。但Gla组血糖波动更小,达到良好血糖控制的所需时间明显缩短(P<0.01);Gla组胰岛素用量、低血糖发生率、切口感染或延迟愈合率均少于MDI组(P<0.05)。结论甘精胰岛素治疗能有效、安全、平稳、迅速地控制血糖,尤其适用于需要更有效补充基础胰岛素治疗阶段的糖尿病围手术期患者,值得临床推广运用。
Objective To observe the clinical effectivity and safety of Glargine treatment in perioperative patient with type 2 diabetes. Methods 60 T2DM patients scheduled for surgery were divided into glargine insulin group （Gla, n=30） and MDI group （Humulin N, n=30）. The Dosage was adjusted according to a blood glucose fluctuations to compare the effect and safety between the two groups. Results The levels of blood glucose in the two groups were reduced after treatments （P〈0.01） and there is no significant difference in hypoglycemic effect between the two groups （P〉0.05）. But the blood glucose fluctuation was smaller in Gla group than in MDI group and the glucose target arrival time was shorter in Gla group than in MDI group （P〈0. 01）. The insulin dosage, the incidences of hypoglycemia and wound infection and delayed healing rate were less in Gla group than in MDI group （P〈0. 05）. Conclusions Glargine treatment can effectively, rapidly and savely control the blood glucose and is especially suitable for the perioperative patient requiring a sufficient basal insulin.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2011年第5期335-337,共3页
Chinese Journal of Diabetes
关键词
糖尿病
2型
围手术期
甘精胰岛素
Diabetes mellitus, type 2
Perioperative period
Insulin glargine
